Oncotargets And Therapy SCIE

国际简称：ONCOTARGETS THER 参考译名：肿瘤靶点和治疗

主要研究方向：BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY 预警期刊审稿周期：较慢,6-12周

《肿瘤靶点和治疗》(Oncotargets And Therapy)是一本由Dove Medical Press Ltd.出版的以BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本开放期刊。

4区中科院分区
Q3 JCR分区
75 年发文量
2.7 IF影响因子
开放是否OA
44 H-index
2008 创刊年份
1 issue/year 出版周期
English 出版语言

OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer.

The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype.

Specific topics covered by the journal include:

-Novel therapeutic targets and innovative agents

-Novel therapeutic regimens for improved benefit and/or decreased side effects

-Early stage clinical trials

Further considerations when submitting to OncoTargets and Therapy:

-Studies containing in vivo animal model data will be considered favorably.

-Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines.

-Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples.

-Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.

-Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.

-Single nucleotide polymorphism (SNP) studies will not be considered.

[ 查看全部 ]

投稿咨询加急咨询

Oncotargets And Therapy期刊信息

ISSN：1178-6930
出版语言：English
是否OA：开放
E-ISSN：1178-6930
出版地区：ENGLAND
是否预警：是
出版商：Dove Medical Press Ltd.
出版周期：1 issue/year
创刊时间：2008
开源占比：0.9788
Gold OA文章占比：96.46%
OA被引用占比：1
出版国人文章占比：0.86
出版撤稿占比：0.0179...
研究类文章占比：56.00%

Oncotargets And Therapy CiteScore评价数据（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指数

9.7

0.81

0.648

学科类别	分区	排名	百分位
大类：Medicine 小类：Pharmacology (medical)	Q1	23 / 272	91%
大类：Medicine 小类：Oncology	Q1	65 / 404	84%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Oncotargets And Therapy中科院评价数据

中科院 2023年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程与应用微生物 ONCOLOGY 肿瘤学	3区 4区

中科院 2022年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程与应用微生物 ONCOLOGY 肿瘤学	3区 4区

中科院 2021年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程与应用微生物 ONCOLOGY 肿瘤学	3区 4区

中科院 2021年12月基础版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程与应用微生物 ONCOLOGY 肿瘤学	3区 3区

中科院 2021年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程与应用微生物 ONCOLOGY 肿瘤学	3区 4区

中科院 2020年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程与应用微生物 ONCOLOGY 肿瘤学	3区 4区

Oncotargets And Therapy JCR评价数据（2023-2024年最新版）

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：BIOTECHNOLOGY & APPLIED MICROBIOLOGY	SCIE	Q3	90 / 174	48.6%
学科：ONCOLOGY	SCIE	Q3	163 / 322	49.5%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：BIOTECHNOLOGY & APPLIED MICROBIOLOGY	SCIE	Q2	73 / 174	58.33%
学科：ONCOLOGY	SCIE	Q2	135 / 322	58.23%

Oncotargets And Therapy历年数据统计

影响因子

中科院分区

Oncotargets And Therapy中国学者发文选摘

1、Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
Author: Zhang, Xiangming; Ni, Kai; Chen, Huijun

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 87-90. DOI: 10.2147/OTT.S393165
2、Role of Systemic Immunoinflammation Landscape in the Overall Survival of Patients with Leptomeningeal Metastases from Lung Cancer
Author: Wang, Jia-Wei; Yuan, Qing; Li, Li; Cao, Kai-Hua; Liu, Qi; Wang, Hong-Liang; Hu, Ke; Wu, Xi; Wan, Jing-Hai

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 179-187. DOI: 10.2147/OTT.S402389
3、Secondary Sinonasal Collision Tumor of Papillary Squamous Cell Carcinoma and Small Cell Neuroendocrine Carcinoma After Nasopharyngeal Carcinoma Radiotherapy: A Case Report and Literature Review of Sinonasal Collision Carcinomas
Author: Tang, Hao; Wang, Lina; Xu, Wenfeng; Xu, Yujuan; Li, Xianyun; Guo, Deyu

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 91-97. DOI: 10.2147/OTT.S396703
4、Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK-LIMS1 Fusion: A Case Report
Author: Shi, Junmei; Jia, Zhaohui; Zhou, Zhiguo; Zhao, Liyan; Meng, Qingju; Liu, Yibing

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 109-114. DOI: 10.2147/OTT.S388962
5、Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study
Author: Li, Guiling; Cheng, Mingxia; Hong, Kai; Jiang, Yao

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 157-163. DOI: 10.2147/OTT.S400376
6、A Primary Lung and Breast Cancer Patient with Germline EGFR R776H Mutation: A Case Report and Literature Review
Author: Li, Dan; Liu, Xin; Cui, SaiQiong; Yang, DaFu; Zhu, Yue; Pan, Evenki; Yang, Peng; Dai, ZhaoXia

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 17-22. DOI: 10.2147/OTT.S391766
7、Transmission of Exosomal TPX2 Promotes Metastasis and Resistance of NSCLC Cells to Docetaxel
Author: Hu, Jiaru; He, Qing; Tian, Tian; Chang, Na; Qian, Liting

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 197-210. DOI: 10.2147/OTT.S401454
8、A Refractory Case of CDKN2A/B Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib
Author: Fan, Weiming; Wang, Chuan; Zhong, Xuefeng; Zheng, Yating; Chen, Tingting; Huang, Mengli; Su, Shuying

Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 23-29. DOI: 10.2147/OTT.S390458